Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure

Osimertinib is a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR mutations. Pneumonitis is a severe adverse event (AE) related to osimertinib treatment which appears to be more frequent when associated with concurrent or previous anti-PD(L)...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Ecancermedicalscience
Main Authors: Harada, Guilherme, Santini, Fernando Costa, Canedo, Felipe Sales Nogueira Amorim, de Carvalho Oliveira, Leandro Jonata, Zuppani, Henrique Bortot, De Castro, Gilberto
Format: Artigo
Sprog:Inglês
Udgivet: Cancer Intelligence 2019
Fag:
Case Report
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6834382/
https://ncbi.nlm.nih.gov/pubmed/31921341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2019.970
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker